Clinical trials: Diabetes, Type 1
Type 1 Diabetes
A Study on the Safety, Preliminary Efficacy, and Cellular Kinetics of Allo-CD7 CAR-T Cells in T1DM
This is an open clinical pharmacological translational Research Study, aiming to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RD13-02 in patients with aT1DM
- Trial name
- NCT07142161
- Testing
- RD13-02 cell infusion
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Nanjing Bioheng Biotech Co., Ltd.
Type 2 Diabetes Mellitus
A Phase 1 Single/Multiple Dose Study Of PF-06293620 To Assess Safety, Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus
A first in human study to determine the safety, tolerability and pharmacokinetics of single and multiple ascending doses of PF-06293620 in subjects with Type 2 Diabetes Mellitus
- Trial name
- NCT02211261
- Testing
- PF-06293620
- Where
- 7 sites in United States
- Volunteers
- 84 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 1
Benefit/Risk Evaluation of Insuman Implantable Versus Insuplant Using Medtronic MiniMed Implantable Pump System in Patients With Type 1 Diabetes
Primary Objective: To compare Insuman Implantable 400 IU/ml versus Insuplant 400 IU/ml with respect to the pump refill accuracy during a 4 refill cycle period (i.e.
- Trial name
- NCT01194882
- Testing
- HUMAN INSULIN (BIOSYNTHETIC), Insuplant
- Where
- 17 sites in Belgium, France and 2 more
- Volunteers
- 479 people
- Sponsor
- Sanofi
Type 1 Diabetes Mellitus
A Trial to Investigate the Safety and the Pharmacokinetic, Pharmacodynamic Characteristics of Two BioChaperone® Glucagon Formulations Compared to Marketed GlucaGen® in Subjects With T1DM
This is a single centre, double-blind, randomised, three-period crossover phase 1 trial in subjects with type 1 diabetes mellitus (T1DM). Each subject will be randomly allocated to a sequence of three treatments, i.e.
- Trial name
- NCT03176524
- Testing
- BioChaperone® glucagon formulation 1, BioChaperone® glucagon formulation 2, GlucaGen® HypoKit®
- Where
- Germany
- Volunteers
- 27 people
- Sponsor
- Adocia
Diabetes, Diabetes Mellitus, Type 1
A Trial Evaluating the Effect of NN1250 at Steady State Conditions in Subjects With Type 1 Diabetes
This trial was conducted in Europe. The aim of this clinical trial was to evaluate the effect on the blood glucose-lowering effect of NN1250 (insulin degludec) in subjects with type 1 diabetes.
- Trial name
- NCT01114542
- Testing
- insulin degludec, insulin glargine
- Where
- Germany
- Volunteers
- 66 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
User Performance and System Accuracy Evaluations Using Glucose Adjustment
This is an open-label, non-randomised pilot study, to evaluate user performance and system accuracy in blood Glucose monitoring system with glucose adjustment.
- Trial name
- NCT02374879
- Testing
- Blood Glucose Monitoring Systems.
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- LifeScan
Type 1 Diabetes, Type 1 Diabetes (T1D)
Study of IMC-S118AI in Type 1 Diabetes
This is a first-in-human (FIH) study designed to assess the safety, tolerability, and pharmacokinetic (PK) profile of IMC-S118AI in single-ascending dose (SAD) and multiple-ascending dose (MAD) regimens.
- Conditions
- Type 1 Diabetes, Type 1 Diabetes (T1D), Diabetes Type 1
- Trial name
- NCT07493122
- Testing
- IMC-S118AI
- Volunteers
- 154 people
- Sponsor
- Immunocore Ltd
Type I Diabetes Mellitus
Phase 4 Study to Evaluate Treatment Optimization With Once-daily Insulin Glargine 300 U/mL
Primary Objective: To evaluate the efficacy of switching treatment from twice-daily basal insulin to once-daily insulin glargine (U300) as part of basal bolus regime in terms of glycated hemoglobin improvement (reduction by at…
- Trial name
- TOP1 (NCT03406000)
- Testing
- INSULIN GLARGINE (U300)
- Where
- 11 sites in Brazil
- Volunteers
- 170 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the safety and effectiveness of alogliptin combined with metformin, once daily (QD) or twice daily (BID), in participants with Type 2 Diabetes.
- Trial name
- AM7D (NCT01023581)
- Testing
- Alogliptin, Metformin
- Where
- 201 sites in United States, Czechia and 11 more
- Volunteers
- 784 people
- Sponsor
- Takeda
Diabetes, Diabetes Mellitus, Type 1
Observational Study of Safety and Tolerability of Levemir™ FlexPen™ (Insulin Detemir) in the Treatment of Type 1 and Type 2 Diabetes Mellitus
This study is conducted in Asia. The aim of this observational study is to evaluate the safety and tolerability of Levemir™ FlexPen™ (Insulin Detemir) in the treatment of Filipino patients with Type 1 and Type 2 Diabetes Mellitus.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT00655200
- Testing
- insulin detemir
- Where
- Philippines
- Volunteers
- 2,286 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
A Research Study to Look at How Faster Aspart Works in Chinese People With Type 1 Diabetes or Type 2 Diabetes
This study looks at how faster aspart reaches and stays in the blood after injection in Chinese people with type 1 diabetes or type 2 diabetes, compared to the reference product called NovoRapid®.
- Trial name
- NCT04698018
- Testing
- Faster Aspart, Novo Rapid
- Where
- 3 sites in Germany, Hong Kong
- Volunteers
- 23 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Study To Compare Single Dose Of Three Modified Release Formulations Of PF-04937319 With Immediate Release Material-Sparing-Tablet (IR MST) Formulation Previously Studied In Adults With Type 2 Diabetes Mellitus.
Study B1621015 will characterize bioavailability, tolerability and pharmacodynamics of three modified release formulations of PF-04937319 compared with the immediate release material-sparing-tablet (IR MST) formulation in adults…
- Trial name
- NCT02206607
- Testing
- PF-04937319 IR MST, PF-04937319 MR 1, PF-04937319 MR 2
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 1, Diabetes Mellitus
Diamyd Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes
The objective of DIAGNODE-2 is to evaluate the efficacy of Diamyd compared to Placebo, upon administration directly into a lymph node in combination with an oral vitamin D/Placebo regimen, in terms of preserving endogenous…
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Autoimmune Diseases, Metabolic Disease
- Trial name
- NCT03345004
- Testing
- Diamyd, Vitamin D
- Where
- 18 sites in Czechia, Netherlands and 2 more
- Volunteers
- 109 people
- Sponsor
- Diamyd Medical AB
Diabetic Kidney Disease, Chronic Kidney Diseases
Prospective Decision Impact Clinical Utility Trial of KidneyIntelX
The clinical utility trial is designed to evaluate how the results of KidneyIntelX test / platform impacts on the clinical management of type 2 diabetes patients identified as increased risk for rapid kidney function decline…
- Conditions
- Diabetic Kidney Disease, Chronic Kidney Diseases, Chronic Kidney Disease Stage 1, Chronic Kidney Disease Stage 2
- Trial name
- NCT05198284
- Testing
- KidneyIntelX
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Renalytix AI, Inc.
Diabetes, Diabetes Mellitus, Type 1
Comparison of Glycemic Control Achieved With 2 Different Needles
This trial is conducted in the United States of America (USA). The aim of this trial is to investigate if a 31 gauge x 6 mm needle will provide comparable blood glucose control to the 29 gauge x 12.7 mm needle in obese subjects…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Delivery Systems
- Trial name
- NCT00572052
- Testing
- NovoFine® needle 6 mm, Ultra-Fine needle 12.7 mm
- Where
- 5 sites in United States
- Volunteers
- 62 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus (T1DM)
The Effect of Hedia Diabetes Assistant on TiMe-in-range in People With Type 1 Diabetes and Sub-Optimal Glycemic Control in France - A Randomised Controlled Trial.
The goal of this randomized controlled study is to assess the clinical performance and safety of Hedia Diabetes Assistant in adults with type 1 diabetes and suboptimal glycemic control in France.
- Trial name
- TEMPO (NCT06819306)
- Testing
- Hedia Diabetes Assistant
- Where
- 6 sites in France
- Volunteers
- 154 people
- Sponsor
- Hedia ApS
Gastroparesis
Itopride Hydrochloride in Diabetes: Effects on Gastric Emptying and Glycemia
Itopride is a new compound that is already marketed in Japan and in some countries of Eastern Europe under the name of Ganaton. It is used to treat symptoms associated with gastroparesis.
- Trial name
- NCT00370084
- Testing
- Itopride
- Where
- Australia
- Volunteers
- 25 people
- Sponsor
- Forest Laboratories
Diabetes Mellitus, Type 1
Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus
This is a Phase II, randomized, double-blind, parallel group, placebo controlled, multicentre study of 52 weeks treatment duration.
- Trial name
- NCT02284009
- Testing
- Albiglutide weekly injection, Insulin
- Where
- 32 sites in France, Germany and 3 more
- Volunteers
- 67 people
- Sponsor
- GlaxoSmithKline
Diabetes, Diabetes Mellitus, Type 1
Comparison of Insulin Detemir and NPH With Respect to Lowering the Blood Sugar and Symptoms Experienced by Type 1 Diabetics During Hypoglycaemia
This trial is conducted in UK. The aim of this clinical trial is to investigate lowering the blood sugar and symptoms experienced during hypoglycaemia
- Trial name
- NCT00760448
- Testing
- insulin detemir, insulin NPH
- Where
- United Kingdom
- Volunteers
- 25 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
The purpose of the study is to study the clinical effects of the investigational drug, SB-509 versus placebo in patients with diabetic neuropathy.
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy
- Trial name
- NCT00406458
- Testing
- SB-509, Normal Saline
- Where
- 15 sites in United States, Mexico
- Volunteers
- 110 people
- Sponsor
- Sangamo Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.